Nivolumab
A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA.
Year introduced: 2019 (2010)
PubMed search builder options
Subheadings:
Tree Number(s): D12.776.124.486.485.114.224.060.829, D12.776.124.790.651.114.224.060.829, D12.776.377.715.548.114.224.200.829
MeSH Unique ID: D000077594
Registry Number: 31YO63LBSN
Entry Terms:
- MDX-1106
- MDX1106
- MDX 1106
- Opdivo
- BMS-936558
- BMS936558
- BMS 936558
- ONO-4538
- ONO4538
- ONO 4538
Pharmacologic Action: